Cost-effectiveness of data driven personalised antibiotic dosing in critically ill patients with sepsis or septic shock
Authors' conclusion
Data-driven personalised antibiotic dosing in critically ill patients as implemented in the AutoKinetics trial cannot be recommended for implementation as a cost-effective intervention.
Study context
- Population
- Critically ill patients with sepsis or septic shock
- Comparison
- Intervention vs Usual care
- Primary endpoint
- Cost-effectiveness (incremental cost-effectiveness ratios) for QALYs, mortality and pharmacokinetic target attainment; costs from a societal perspective
Methodological detailscost-effectiveness analysis, societal perspective, multiple imputation, bootstrapping, bivariate regression
- Cost-effectiveness analysis
- Societal perspective
- Multiple imputation
- Bootstrapping
- Bivariate regression
Primary result
As reported in the abstract
Costs and effects
- Costs, intervention vs usual care
- €42,684 vs. 39,475
- Mortality, intervention vs usual care
- 42% vs. 49%
- Quality-adjusted life years (QALYs), intervention vs usual care
- 0.184 vs. 0.153
- Pharmacokinetic target attainment, intervention vs usual care
- 69% vs. 48%
- Additional cost to attain targeted plasma levels for one more patient
- €18,129
- Additional cost to save one life
- €55,576
- Additional cost to gain one QALY
- €123,493
Original publication
Cost-effectiveness of data driven personalised antibiotic dosing in critically ill patients with sepsis or septic shock. J Clin Monit Comput. Published 24 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →